Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth Ends Solvay Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Wyeth Ends Solvay Collaboration

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth Pharmaceuticals has ended its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox, an investigational atypical antipsychotic drug, as well as other compounds in earlier stages of development for the potential treatment of schizophrenia and other psychiatric conditions.
   
The collaboration was terminated after Wyeth assessed the opportunity for bifeprunox, and determined it would not have sufficient commercial value for the two companies to share. All development and commercialization rights in North America for bifeprunox, as well as global rights for the other compounds will now revert to Solvay.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters